Replay available

Entera Bio Ltd. (ENTX) Q1 2022 Earnings Call

Entera Bio Ltd. (NASDAQ: ENTX) Q1 2022 earnings conference call, held 2022-05-18. Replay captured from the company's public earnings webcast.

Wed, May 18, 2022 at 8:00 AMendedReplay
Entera Bio Ltd. (ENTX) Q1 2022 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Rich Cockrell

Investor Relations

Spiros Dramas

Chief Executive Officer

Miranda Toledano

Chief Business Officer, Chief Financial Officer, and Head of Strategy

Kalpit Patel

Analyst, B. Riley

Nathan Weinstein

Analyst, Aegis Capital

Replay transcript excerpt

Greetings and welcome to Interrobio's first quarter 22 update conference call. At this time, all participants are in a listen-only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to Rich Cockrell of Investor Relations. Thank you. You may begin. Good morning and welcome to the call. Joining me today are Spiros Dramas, our Chief Executive Officer, and Miranda Teledano, Chief Business Officer, Chief Financial Officer, and Head of Strategy. A press release announcing Interis financial and operating results for the first quarter ended March 31st, 2022, was issued on May 12th, 2022. For those of you who have not received it, it is available on the company's website in the investor section. at www.interrobio.com. Before we begin our prepared remarks, I would like to remind you that various statements the company makes during this call about future results in operations and financial positions are or interpretations of data from completed and ongoing trials, business strategy, and plans and objectives for the company's future operations are considered to be forward-looking statements within the meaning of the federal securities laws. Our forward-looking statements are based upon current expectations that involve risk, changes in circumstances, assumptions, and uncertainties. Specifically, developments related to the COVID-19 pandemic continue to evolve, and the extent to which the pandemic will impact us in the future will depend on the duration and magnitude of such impact, and on numerous factors that we may not be able to accurately predict. T...

More from Entera Bio Ltd.